Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Feb
24
Today In Oncology
Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Acral Melanoma Ancestry and Genetics Impact Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo